1.Any effect of CYP2C9 variants on warfarin clearance in Chinese patients?

You, JHS, Zuo, Z, Lo     More...

You, JHS, Zuo, Z, Lo, CMY, Zhou, L, Yiu, HHW, Chau, CTS, Choi, KC, Choi, DKM, Wong, RSM, Cheng, G     Less

THROMBOSIS AND HAEMOSTASIS[0340-6245], Published 2007, Volume 97, Issue 5, Pages 866-868

收錄情况： WOS SCOPUS

WOS核心合集引用: 3  2023影響因子:  5.0  发表年影響因子:  3.501 

2.The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis

You, JHS, Chan, FWH,     More...

You, JHS, Chan, FWH, Wong, RSM, Cheng, G     Less

THROMBOSIS AND HAEMOSTASIS[0340-6245], Published 2004, Volume 92, Issue 3, Pages 590-597

收錄情况： WOS SCOPUS

WOS核心合集引用: 52  2023影響因子:  5.0  发表年影響因子:  3.413 

3.Cost-effectiveness of two models of management for patients on chronic warfarin therapy - a Markov model analysis

You, JHS, Chan, FWH,     More...

You, JHS, Chan, FWH, Wong, RSM, Cheng, G     Less

THROMBOSIS AND HAEMOSTASIS[0340-6245], Published 2003, Volume 90, Issue 6, Pages 1106-1111

收錄情况： WOS SCOPUS

WOS核心合集引用: 15  2023影響因子:  5.0  发表年影響因子:  4.950